vs
ARDELYX, INC.（ARDX）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是ARDELYX, INC.的1.5倍（$193.5M vs $125.2M），ARDELYX, INC.同比增速更快（7.8% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $20.6M），过去两年ARDELYX, INC.的营收复合增速更高（64.9% vs 18.2%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
ARDX vs MCS — 直观对比
营收规模更大
MCS
是对方的1.5倍
$125.2M
营收增速更快
ARDX
高出5.1%
2.8%
自由现金流更多
MCS
多$5.8M
$20.6M
两年增速更快
ARDX
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $193.5M |
| 净利润 | $-407.0K | — |
| 毛利率 | 91.3% | — |
| 营业利润率 | 4.1% | 0.9% |
| 净利率 | -0.3% | — |
| 营收同比 | 7.8% | 2.8% |
| 净利润同比 | -108.8% | — |
| 每股收益（稀释后） | $-0.01 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXMCS
| Q4 25 | $125.2M | $193.5M | ||
| Q3 25 | $110.3M | $210.2M | ||
| Q2 25 | $97.7M | $206.0M | ||
| Q1 25 | $74.1M | $148.8M | ||
| Q4 24 | $116.1M | $188.3M | ||
| Q3 24 | $98.2M | $232.7M | ||
| Q2 24 | $73.2M | $176.0M | ||
| Q1 24 | $46.0M | $138.5M |
净利润ARDXMCS
| Q4 25 | $-407.0K | — | ||
| Q3 25 | $-969.0K | $16.2M | ||
| Q2 25 | $-19.1M | $7.3M | ||
| Q1 25 | $-41.1M | $-16.8M | ||
| Q4 24 | $4.6M | $986.0K | ||
| Q3 24 | $-809.0K | $23.3M | ||
| Q2 24 | $-16.5M | $-20.2M | ||
| Q1 24 | $-26.5M | $-11.9M |
毛利率ARDXMCS
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — | ||
| Q1 24 | 84.5% | — |
营业利润率ARDXMCS
| Q4 25 | 4.1% | 0.9% | ||
| Q3 25 | 4.2% | 10.8% | ||
| Q2 25 | -14.7% | 6.3% | ||
| Q1 25 | -49.0% | -13.7% | ||
| Q4 24 | 7.0% | -1.2% | ||
| Q3 24 | 2.3% | 14.1% | ||
| Q2 24 | -18.6% | 1.3% | ||
| Q1 24 | -53.6% | -12.0% |
净利率ARDXMCS
| Q4 25 | -0.3% | — | ||
| Q3 25 | -0.9% | 7.7% | ||
| Q2 25 | -19.5% | 3.6% | ||
| Q1 25 | -55.5% | -11.3% | ||
| Q4 24 | 4.0% | 0.5% | ||
| Q3 24 | -0.8% | 10.0% | ||
| Q2 24 | -22.5% | -11.5% | ||
| Q1 24 | -57.6% | -8.6% |
每股收益（稀释后）ARDXMCS
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $-0.11 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $23.4M |
| 总债务越低越好 | $202.8M | $159.0M |
| 股东权益账面价值 | $166.9M | $457.4M |
| 总资产 | $501.6M | $1.0B |
| 负债/权益比越低杠杆越低 | 1.21× | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资ARDXMCS
| Q4 25 | $68.0M | $23.4M | ||
| Q3 25 | $42.7M | $7.4M | ||
| Q2 25 | $90.0M | $14.9M | ||
| Q1 25 | $30.8M | $11.9M | ||
| Q4 24 | $64.9M | $40.8M | ||
| Q3 24 | $47.4M | $28.4M | ||
| Q2 24 | $41.9M | $32.8M | ||
| Q1 24 | $36.1M | $17.3M |
总债务ARDXMCS
| Q4 25 | $202.8M | $159.0M | ||
| Q3 25 | $202.1M | $162.0M | ||
| Q2 25 | $201.4M | $179.9M | ||
| Q1 25 | $151.3M | $198.9M | ||
| Q4 24 | $150.9M | $159.1M | ||
| Q3 24 | $100.7M | $173.1M | ||
| Q2 24 | $100.2M | $175.7M | ||
| Q1 24 | $99.8M | $169.8M |
股东权益ARDXMCS
| Q4 25 | $166.9M | $457.4M | ||
| Q3 25 | $154.3M | $454.3M | ||
| Q2 25 | $139.5M | $448.4M | ||
| Q1 25 | $145.7M | $441.8M | ||
| Q4 24 | $173.3M | $464.9M | ||
| Q3 24 | $158.3M | $462.3M | ||
| Q2 24 | $147.0M | $449.4M | ||
| Q1 24 | $150.9M | $459.3M |
总资产ARDXMCS
| Q4 25 | $501.6M | $1.0B | ||
| Q3 25 | $486.2M | $1.0B | ||
| Q2 25 | $466.8M | $1.0B | ||
| Q1 25 | $410.2M | $1.0B | ||
| Q4 24 | $435.8M | $1.0B | ||
| Q3 24 | $367.9M | $1.0B | ||
| Q2 24 | $343.5M | $1.1B | ||
| Q1 24 | $342.4M | $1.0B |
负债/权益比ARDXMCS
| Q4 25 | 1.21× | 0.35× | ||
| Q3 25 | 1.31× | 0.36× | ||
| Q2 25 | 1.44× | 0.40× | ||
| Q1 25 | 1.04× | 0.45× | ||
| Q4 24 | 0.87× | 0.34× | ||
| Q3 24 | 0.64× | 0.37× | ||
| Q2 24 | 0.68× | 0.39× | ||
| Q1 24 | 0.66× | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.0M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $20.6M | $26.4M |
| 自由现金流率自由现金流/营收 | 16.4% | 13.6% |
| 资本支出强度资本支出/营收 | 0.3% | 11.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-44.0M | $989.0K |
8季度趋势，按日历期对齐
经营现金流ARDXMCS
| Q4 25 | $21.0M | $48.8M | ||
| Q3 25 | $365.0K | $39.1M | ||
| Q2 25 | $-25.3M | $31.6M | ||
| Q1 25 | $-38.5M | $-35.3M | ||
| Q4 24 | $9.8M | $52.6M | ||
| Q3 24 | $501.0K | $30.5M | ||
| Q2 24 | $-19.4M | $36.0M | ||
| Q1 24 | $-35.7M | $-15.1M |
自由现金流ARDXMCS
| Q4 25 | $20.6M | $26.4M | ||
| Q3 25 | $209.0K | $18.2M | ||
| Q2 25 | $-26.0M | $14.7M | ||
| Q1 25 | $-38.8M | $-58.3M | ||
| Q4 24 | $9.2M | $27.1M | ||
| Q3 24 | $364.0K | $12.0M | ||
| Q2 24 | $-19.5M | $16.1M | ||
| Q1 24 | $-35.9M | $-30.5M |
自由现金流率ARDXMCS
| Q4 25 | 16.4% | 13.6% | ||
| Q3 25 | 0.2% | 8.7% | ||
| Q2 25 | -26.6% | 7.1% | ||
| Q1 25 | -52.3% | -39.2% | ||
| Q4 24 | 7.9% | 14.4% | ||
| Q3 24 | 0.4% | 5.2% | ||
| Q2 24 | -26.7% | 9.2% | ||
| Q1 24 | -77.9% | -22.0% |
资本支出强度ARDXMCS
| Q4 25 | 0.3% | 11.6% | ||
| Q3 25 | 0.1% | 9.9% | ||
| Q2 25 | 0.7% | 8.2% | ||
| Q1 25 | 0.4% | 15.5% | ||
| Q4 24 | 0.5% | 13.5% | ||
| Q3 24 | 0.1% | 7.9% | ||
| Q2 24 | 0.2% | 11.3% | ||
| Q1 24 | 0.3% | 11.1% |
现金转化率ARDXMCS
| Q4 25 | — | — | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 4.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| Product IBSRELA | $86.6M | 69% |
| Product XPHOZAH | $27.8M | 22% |
| Other | $10.8M | 9% |
| Non Cash Royalty Related To Sale Of Future Royalties | $1.4M | 1% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
